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Abstract — This study evaluated the cardiovascular effects of a constant rate infusion (CRI) of lidocaine, lidocaine 
and dexmedetomidine, and dexmedetomidine in dogs anesthetized with sevoflurane at equipotent doses. Treatments 
consisted of T1-Lidocaine [loading dose 2 mg/kg body weight (BW), IV, and CRI of 100 !g/kg BW per min] at 
1.4% end-tidal of sevoflurane (FESEV); T2-Dexmedetomidine (loading dose 2 !g/kg BW, IV, and CRI of 2 !g/kg 
BW per hour) and FESEV 1.1%; and T3-Lidocaine-Dexmedetomidine using the same doses of T1 and T2 and 
FESEV 0.8%. Constant rate infusion of lidocaine did not induce any cardiovascular changes; lidocaine and 
dexmedetomidine resulted in cardiovascular effects similar to dexmedetomidine alone. These effects were 
characterized by a significant (P " 0.001) decrease in heart rate, cardiac output, cardiac index, oxygen delivery, 
and pulmonary vascular resistance index, and a significant (P " 0.001) increase in mean and diastolic arterial 
pressure, systemic vascular resistance index, pulmonary arterial occlusion pressure and oxygen extraction ratio, 
compared with baseline values. In conclusion, a CRI of lidocaine combined with dexmedetomidine produces 
significant cardiovascular changes similar to those observed with dexmedetomidine alone.
Résumé — Effets cardiovasculaires des infusions constante de taux de lidocaïne, lidocaïne et dexmédétomidine, 
et dexmédétomidine chez chiens anesthésier at équipotent doses de sevoflurane. L’objet de cette etude a été la 
evaluation des effets cardo-vasculaires de la perfusion à debit continue (CRI) de lidocaïne, lidocaïene et 
dexmédétomidine, et dexmédétomidine en chiens anesthésiés avec sévoflurane dans équipotentiel dose. Les 
traitemets consistèrent á T1-Lidocaïne [dose de charge de 2 mg/kg, IV, et perfusion à debit continue (CRI) de 
100 !g/kg/min] en 1,4 % en fin d’expiration du sévoflurane (FESEV); T2-Déxmédetomidine (dose de charge de 
2 !g/kg, IV, et perfusion à debit continue (CRI) de 2 !g/kg/h) et FESEV 1,1 % et T3-Lidocaïne-Dexmédétomidine 
en utilisant la même dose de T1 et T2 et FESEV 0,8 %. Perfusion à debit continue (CRI) de lidocaïne ne induit 
pas aucun échange cardio-vasculaire; lidocaïne et dexmédétomidine resulta dans effets cardio-vasculaires similaires 
a dexmédétomidine seule. Ces effets caracterices par significative décroissance (P " 0,001) en fréquence cardiaque, 
le débit cardiaque, index cardiaque, la libération de l’oxygène, pulmonaire indice de résistance vasculaire, et 
significative accroissement de la moyenne a la pression artériele diastolique (P " 0,001), indice de résistance 
vasculaire systémique, et l’extraction d’oxygène. En somme, la perfusion à debit continue (CRI) de lidocaïne 
produit significative échange cardio-vasculaire similaire à ceux observe en itilisant seulement dexmédétomidine.
(Traduit par les auteurs)
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M aintenance of general anesthesia with inhalational anes-thetics allows for adequate control of anesthetic depth 
and a fast recovery. However, a major concern is the dose-
dependent cardiopulmonary depression that occurs with higher 
concentrations of inhalational anesthetics. The inclusion of an 
injectable analgesic and/or sedative and/or anesthetic drug allows 
a more balanced technique and may result in a sparing effect on 
the minimum alveolar concentration (MAC) of the inhalational 
anesthetic with a potential reduction in the dose-dependent 
adverse effects (1–4).
Alpha 2-adrenergic agonists, such as dexmedetomidine and 
medetomidine, have been included as part of balanced anesthetic 
techniques in dogs and other species, due to their analgesic and 
inhalational anesthetic sparing effects (2,4–11). Their profound 
effects on the cardiovascular system at doses used commonly in 
veterinary practice include a decrease in cardiac output, heart 
rate, sympathetic tone, and an increase in afterload from increases 
in systemic vascular resistance, which may result in an increase in 
systemic and occasionally pulmonary pressures (11–18). These 
effects can be minimized and shortened when low doses are 
administered in humans and dogs (2,5,7,10,14,18–21).
Lidocaine has been used intravenously as an analgesic during 
surgery and for its MAC sparing properties with minimal cardio-
vascular effects in dogs and horses (3,4,22–27). The cardiorespi-
ratory effects of a combination of lidocaine and medetomidine as 
a constant rate infusion (CRI) for balanced anesthesia have been 
determined in horses and included higher blood pressure, less 
inotropic support, lower inhalational anesthetic requirements, 
and similar cardiac index when compared to a control group 
(6,28). The MAC sparing effects for isoflurane and sevoflurane of 
a combination of CRIs of lidocaine and dexmedetomidine have 
been determined in dogs (29,30), but not the cardiopulmonary 
effects of these CRIs with sevoflurane. The purpose of this study 
was to investigate if the benefits observed in other species from 
CRIs of lidocaine and/or dexmedetomidine combined with 
inhalational anesthetics are also present in dogs anesthetized 
with sevoflurane at equipotent doses. Our hypothesis was that 
in sevoflurane-anesthetized dogs, a CRI of dexmedetomidine 
with or without lidocaine is characterized by dexmedetomidine 
cardiovascular effects, compared with a CRI of lidocaine alone.
Materials and methods
Animals
Three male and 3 female adult mixed breed neutered dogs, 
3.4 # 0.8 y old (mean # SD), weighing 18.4 # 5 kg were 
included in a prospective randomized crossover experiment with 
a 2-week washout period between treatments. Dogs were healthy 
based on medical history, physical examination, complete blood 
(cell) count (CBC), and serum biochemical analysis. The Animal 
Research Ethics Committee of the Universidad Autónoma de 
Mexico approved this study (protocol # DCARM-1412).
Anesthetic procedure and instrumentation
Food but not water was withheld for 8 h prior to each anes-
thetic procedure. A 20-gauge catheter (BD; Becton Dickinson 
and Company, New Jersey, USA) was aseptically placed into 
the cephalic vein. Anesthesia was induced via facemask using 
a vaporizer setting of 8% of sevoflurane (Sevorane; Abbott 
Laboratories, Bogotá, Colombia) and a fresh gas flow of 
4 L/min. Dogs were orotracheally intubated and attached to 
a circle anesthetic rebreathing system (Fabius; Dragër Medical 
GmbH 23542, Lübeck, Germany), placed in lateral recumbency 
and mechanically ventilated with intermittent positive-pressure 
ventilation (IPPV) to maintain eucapnia (35 to 40 mmHg end 
tidal CO2). Monitoring included end-tidal sevoflurane and 
CO2 concentrations using a side-stream infrared gas analyzer 
(Dräger Vamos; Dräger Medical GmbH) with the sampling 
port attached between the endotracheal tube and the breathing 
system. The anesthesia monitor was calibrated each morning 
using a calibration gas specifically designed for this purpose 
(DOT-34 NRC 300/375M1014; Datex-Ohmeda Division, 
Helsinki, Finland). Anesthesia was maintained with sevoflurane 
vaporized in 100% oxygen with a flow rate of 2 L/min and the 
end-tidal concentration (FESEV) maintained at 2.8% while the 
instrumentation was completed.
An isotonic fluid solution (Hartman Solution, HT, Pisa 
Agropecuaria, Mexico) was administered at a flow rate of 
3 mL/kg body weight (BW) per hour through the cephalic cath-
eter by use of an infusion pump (Colleague; Baxter Healthcare 
Corporation, Deerfield, Illinois, USA). An electrocardiogram 
(lead II) for heart rate (HR) and rhythm was continuously 
monitored by placing electrodes at the level of the elbows 
and left patella, and a pulse oximeter probe attached to the 
dog’s tongue (BeneView T8; Shenzhen Mindray Bio-Medical 
Electronics, Shenzhen, China). A 22-gauge catheter was asepti-
cally placed in the dorsal metatarsal artery and attached to a 
transducer (DTX plus DT 4812; Becton Dickinson Critical 
Care Systems, Singapore). The transducer was previously veri-
fied against a mercury manometer at 50, 100, and 200 mmHg, 
and zeroed at the level of the manubrium for direct monitoring 
of arterial blood pressure [systolic (SAP), diastolic (DAP), and 
mean (MAP)]. Blood was collected and placed into lithium 
heparin syringes (A-Line; Becton, Dickson and Company, 
Oxford, UK), for determination of pH, arterial partial pressure 
of carbon dioxide (PaCO2) and oxygen (PaO2), packed cell vol-
ume, hemoglobin, bicarbonate, lactate, and glucose at the dog’s 
corrected body temperature, using a blood gas analyzer (GEM 
Premier 3000; Instrumentation Laboratory, Warrington, UK). 
The gas analyzer was calibrated before each experiment by using 
2 aqueous buffered solutions containing precise concentrations 
of CO2 and O2.
A 7-Fr 4 lumen 110 cm Swan-Ganz catheter (Arrow Balloon 
Thermodilution Set; Arrow International, Morrisville, North 
Carolina, USA) was introduced through the jugular vein using 
an introducer (Introducer kit; Arrow International) for deter-
mination of cardiac output (CO) by thermodilution (COM-1 
Cardiac Output Computer; Edwards Life Sciences, Irvine, 
California, USA). The distal port of this catheter was connected 
to another pressure transducer and advanced into the pulmonary 
artery using the characteristic pressure wave changes associated 
with the right ventricle and pulmonary artery. The transducer 
was connected to the distal port of the Swan-Ganz catheter, 
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zeroed at the level of the manubrium to allow measurement of 
mean pulmonary arterial pressure (MPAP) and pulmonary arte-
rial occlusion pressure (PAOP), and switched to the proximal 
port for measurement of central venous pressure (CVP). For 
CO determinations, 5 mL of dextrose (Dextrose 5%; Solution 
DX-5; Pisa Farmaceutica, Mexico City, Mexico) iced to a 
temperature of 1°C to 4°C was rapidly hand-injected into the 
proximal port of the Swan-Ganz catheter at end-expiration. At 
each measurement time, 3 consecutive measurements that were 
within 10% of each other were recorded and their average taken 
as CO (L/min). The thermistor on the Swan-Ganz catheter was 
used to measure core body temperature (T), which was main-
tained between 37.5°C and 38°C. Samples of mixed venous 
blood were anaerobically collected for gas analysis.
Experimental protocol and measurements
The FESEV was adjusted to 1.8% after instrumentation and 
maintained for 30 min to establish baseline values for CO, 
HR, CVP, SAP, DAP, MAP, and MPAP. From these values, the 
following parameters were calculated:
• cardiac index (CI) (mL/min per kg BW), CI = CO/BW;
• stroke volume index (SVI; mL/beat per kg BW),  
SVI = CI/HR;
• pulmonary vascular resistance index (PVRI; mmHg/mL 
per min per kg BW) = [(MPAP — PAOP)/CI];
• systemic vascular resistance index (SVRI; mmHg/mL 
per min per kg BW) = [(MAP — CVP)/CI];
• oxygen delivery (DO2; mL O2/min per kg BW) =  
(CaO2 $ CI)/100), where CaO2 (arterial oxygen content 
in mL O2/dL) = (Hemoglobin $ Saturation $ 1.34) % 
(0.0031 $ PaO2);
• oxygen consumption (VO2; mL O2/min/kg BW) =  
[(CaO2 — CmvO2) $ CI]/100, where CmvO2 (mixed 
venous oxygen content in mL O2/dL) = (Hemoglobin $ 
Saturation $ 1.34) % (0.0031 $ PvO2); and
• oxygen extraction ratio (ERO2; %) = (VO2/DO2) $ 100 (31).
Each dog received 1 of the following 3 treatments on sepa-
rate anesthetic occasions, assigned by a randomization scheme 
(http://www.randomization.com). T1-Lidocaine (LID)-loading 
dose of lidocaine (Lidocaína 2% Inyectable: Pisa, México), 
2 mg/kg BW, IV, followed immediately by a CRI of 100 !g/kg 
BW per min; T2-Dexmedetomidine (DEX)-loading dose of 
dexmedetomidine (Dexdomitor; Orion Corporation, Espoo, 
Finland), 2 !g/kg BW, IV, followed by a CRI of 2 !g/kg BW 
per hour; and T3-Lidocaine-Dexmedetomidine (LID-DEX) 
at the same doses as T1 and T2. Loading doses were diluted 
up to a final volume of 3 mL with sterile water and injected 
over 10 s. Treatments for the CRI were diluted into 60 mL 
of saline (Saline 0.9%; Solution DX-CS; Pisa Farmaceutica) 
and delivered using a pump infusion device (Colleague; Baxter 
Healthcare Corporation). The solution for the LID group was 
prepared by adding 6 mL of lidocaine 2% to 54 mL of saline, 
resulting in 2 mg of lidocaine per mL. For the DEX group, 
0.08 mL of dexmedetomidine 0.05% was added to 59.9 mL 
of saline, resulting in 0.66 !g of dexmedetomidine per mL. 
For the LID-DEX group, 6 mL of lidocaine and 0.08 mL of 
dexmedetomidine were added to 53.9 mL of saline, resulting 
in the same concentrations of each drug as for the LID and 
DEX groups. These concentrations correspond to an infusion 
rate of 0.05 mL/kg BW per min of any of the solutions. The 
FESEV was decreased for each treatment to 1.4% for group 
LID, 1.1% for group DEX, and 0.8% for group LID-DEX, 
based on MAC equipotent doses previously determined (30). 
A second set of measurements was completed after 45 min of 
CRI administration.
For recovery from anesthesia the CRIs and sevoflurane 
administration were discontinued. Upon return of reflexes and 
spontaneous breathing, the dogs were disconnected from the 
anesthesia machine and extubated when a swallowing reflex was 
present. After recovery, dogs received carprofen (Rimadyl; Pfizer 
Animal Health, Capelle a/d I Jssel, The Netherlands) 4 mg/kg 
BW, SQ, q24h for 2 d. All dogs were rehomed after this experi-
ment was completed.
Statistical analysis
Statistical analysis was performed using Prism 6.0 computer 
software (GraphPad Software; La Jolla, California, USA). The 
Shapiro-Wilk test was used for the assessment of normality. Data 
were examined with a 2-way repeated measures analysis of vari-
ance (ANOVA) to compare the effect of treatment with baseline 
and for comparisons between treatments. The Holm-Sidak test 
was used for multiple comparisons between means of treatments 
(32). Data are reported as mean # standard deviation (SD). 
Statistical significance was accepted at P " 0.05.
Results
Baseline values for each of the 3 treatments were completed 
approximately 45 min after induction (Table 1). Following the 
dexmedetomidine CRI administration, HR, CO, CI, PVRI, 
and DO2 were significantly decreased with respect to base-
line in both the DEX and LID-DEX groups (P " 0.0001) 
and the LID CRI group; whereas MAP (P " 0.0005), DAP 
(P " 0.0005), PAOP (P " 0.0001), SVRI (P " 0.0001), and 
O2ER (P " 0.0001) were significantly increased in both the 
DEX and LID-DEX groups with respect to baseline and the 
LID group. All dogs receiving dexmedetomidine (DEX) showed 
second-degree atrioventricular block in the first 20 min after 
administration.
Arterial blood gas values, lactate, and glucose were within 
normal range and not significantly different between groups. 
Mean and SD lower and upper values were 7.38 # 0.004 and 
7.39 # 0.009 for pH, 35 # 1.0 and 37 # 1.2 mmHg for 
PaCO2, 487 # 25 and 503 # 16 mmHg for PaO2, 22 # 1 and 
23 # 2 mmol/L for bicarbonate, 1.0 # 0.1 and 1.1 # 0.1 mmol/L 
for lactate, and 9.1 # 2.0 and 9.8 # 1.1 mmol/L for glucose.
Discussion
In this study equipotent anesthetic doses of LID-DEX and DEX 
in combination with sevoflurane in dogs resulted in similar 
cardiovascular effects, characterized by significant increases 
in SVR and MAP, with concomitant decreases in HR and 
CO, compared with an equipotent dose of LID combined 
with sevoflurane, which did not induce any alterations in 
cardiovascular parameters. The cardiovascular effects in the 
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LID-DEX and DEX groups are mostly related to the effects 
of DEX, which are induced in both conscious and anesthe-
tized dogs (2,5,7,9–12,17,20). Similar cardiovascular effects of 
increased MAP and decreased HR and CO have been reported 
in horses anesthetized with isoflurane, receiving CRIs of LID-
medetomidine when compared to LID (6). In our study the 
decrease in CO from baseline in the DEX group (42%) and 
LID-DEX group (41%) was due to a decrease in HR that was 
of similar magnitude within each group, since CO = HR $ SV, 
and SV was not affected by either treatment. Cardiac output 
was not affected in the LID group, similar to another study in 
healthy dogs and dogs with subaortic stenosis administered doses 
of up to 200 !g/kg BW per min (33).
The effects of medetomidine and DEX on CO are dose-
related (7,10,11,17,21). In isoflurane-anesthetized dogs, 
medetomidine, which is considered half as potent as DEX for its 
sedative and cardiorespiratory effects (34,35), caused a decrease 
in CO of 15%, 22%, 27%, 44%, 48%, and 61% with IV load-
ing doses of 0.2, 0.5, 1.0, 1.7, 4, and 12 !g/kg BW, followed 
by equal corresponding CRIs (!g/kg BW per hour), respectively 
(7). Similarly, in isoflurane-anesthetized dogs, DEX caused a 
decrease in CO of 19%, 30%, and 58% with IV loading doses 
of 0.5, 1.2, and 3 !g/kg BW, followed by equal corresponding 
CRIs (!g/kg BW per hour), respectively (10,17). In our study, 
the approximately 40% decrease in CO from administering an 
IV dose of 2 !g/kg BW and CRI of 2 !g/kg BW per hour of 
DEX in sevoflurane-anesthetized dogs is also in agreement with 
those studies.
Heart rate is also affected in a dose-dependent manner by 
medetomidine and DEX in isoflurane-anesthetized dogs. In 
general, lower loading doses followed by equal corresponding 
CRIs (!g/kg BW per hour) of medetomidine (" 1.7 !g/kg 
BW) decreased HR to a maximum 36%, whereas higher doses 
(& 4 !g/kg BW) and equal corresponding CRIs (!g/kg BW 
per hour) decreased HR by up to 45% (7). For DEX, lower 
doses (" 1.2 !g/kg BW) followed by equal corresponding CRIs 
(!g/kg BW per hour) decreased HR to a maximum of 33%, 
whereas doses of 3 !g/kg BW and equal corresponding CRIs 
(!g/kg BW per hour) decreased HR by up to 62% (2,10,17). 
In our study, HR decreased by 39% in the DEX group, using 
a dose of 2 !g/kg BW and CRI of 2 !g/kg BW per hour. This 
dose is equivalent to 4 !g/kg BW per hour of medetomidine 
and the decrease in HR is similar to the 45% decrease induced 
by that dose (7). The decrease in HR in the DEX-LID was less 
(33%), and although not significantly different from the DEX 
group, it could have been less because LID has a vagolytic effect 
under conditions of increased vagal activity, which results in an 
increase in the rate of discharge between the sinoatrial node and 
upper Bundle of His (36). Baseline HR did not change after 
administration of LID in the LID group, which is similar to 
results from other studies in dogs anesthetized with isoflurane or 
sevoflurane (3,4,25,29,30), and has also been shown to increase 
with LID (33).
Pulmonary arterial occlusion pressure increased from base-
line by 118% and 92% in in the DEX and LID-DEX groups, 
respectively. The SVRI followed a similar pattern, increasing by 
119% and 125%, respectively. Similar findings are reported in 
other studies for these 2 variables in dogs and cats (10,17,37). 
The increase in PAOP is the result of a lower CO (38), whereas 
the increase in SVRI is through direct vasoconstriction actions of 
alpha-2 agonists on the smooth muscle of blood vessels (39). In 
our study MPAP did not change, which is similar to other studies 
in halothane-anesthetized dogs and halothane-anesthetized sheep 
that received medetomidine (11,40), but PVRI decreased signifi-
cantly in our study in the DEX and LID-DEX group, due to the 
increase in PAOP. Other studies have also shown no significant 
changes in PVRI after medetomidine (40). Differences between 
vascular resistance of the pulmonary and systemic circulation 
have been attributed to the alpha-receptor density, which is lower 
in the pulmonary than the systemic vasculature and may partly 
Table 1. Baseline and 45-minute post-treatment cardiopulmonary parameters of 6 dogs anesthetized with sevoflurane and administered 
lidocaine (T1-LID), dexmedetomidine (T2-DEX), or the combination lidocaine-dexmedetomidine (T3-LID-DEX). Dogs were administered an 
IV loading dose of lidocaine, 2 mg/kg BW, followed by a CRI of 100 !g/kg BW per min (T1-LID and T3-LID-DEX), and an IV loading dose 
of dexmedetomidine, 2 !g/kg BW, followed by a CRI of 2 !g/kg BW per hour (T2-DEX and T3-LID-DEX). Data are expressed as 
mean # SD
Parameters Baseline T1 T1-LID Baseline T2 T2-DEX Baseline T3 T3-LID-DEX
FESEV % 1.82 # 0.17 1.3 # 0.08 1.82 # 0.17 1.1 # 0.23 1.82 # 0.17 0.78 # 0.14
HR (beats/min) 112 # 11 115 # 13 116 # 14 68 # 6a,b 115 # 13 74 # 7a,b
CO (L/min) 3.3 # 0.5 3.3 # 0.4 3.3 # 0.4 1.9 # 0.2a,b 3.4 # 0.5 2.0 # 0.2a,b
CI (mL/min per kg BW) 178 # 27 178 # 22 179 # 23 103 # 11a,b 184 # 28 108 # 11a,b
SAP (mmHg) 118 # 10 117 # 9 117 # 9 119 # 11 119 # 11 117 # 10
DAP (mmHg) 77 # 2 81 # 3 76 # 5 90 # 5a,b 77 # 5 91 # 6a,b
MAP (mmHg) 90 # 2 92 # 2 89 # 6 98 # 3a,b 91 # 7 99 # 4a,b
CVP (mmHg) 3 # 0.4 3 # 0.2 3 # 0.7 4 # 1.0 3 # 0.8 4 # 1.0
SVI (mL/beat per kg BW) 1.6 # 0.2 1.5 # 0.4 1.5 # 0.7 1.5 # 0.7 1.6 # 0.8 1.5 # 0.6
MPAP (mmHg) 14 # 0.4 14 # 0.5 14 # 0.8 15 # 0.7 14 # 1 14 # 0.4
PAOP (mmHg) 5.6 # 0.5 7.0 # 1.0 5.5 # 0.4 12.0 # 1.1a,b 5.7 # 0.6 11 # 0.7a,b
SVRI (mmHg/mL per min per kg BW) 0.49 # 0.06 0.50 # 0.08 0.48 # 0.03 0.91 # 0.02a,b 0.45 # 0.03 0.88 # 0.03a,b
PVRI (mmHg/mL per min per kg BW) 0.05 # 0.006 0.04 # 0.005 0.05 # 0.003 0.03 # 0.003a,b 0.05 # 0.002 0.03 # 0.003a,b
DO2 (mL/min per kg BW) 30.3 # 1.5 29.3 # 2.0 30.5 # 1.6 19.9 # 2.0a,b 29.6 # 1.1 20.5 # 1.7a,b
VO2 (mL/min per kg BW) 5.0 # 0.4 5.0 # 0.5 5.0 # 0.4 5.4 # 0.4 5.0 # 0.4 5.2 # 0.4
O2ER (%) 16.5 # 2.7 17.1 # 2.5 16.4 # 2.5 27.1 # 2.0a,b 16.9 # 2.7 25.4 # 2.4a,b
T (°C) 38.2 # 0.2 38.1 # 0.1 38.2 # 0.1 38.1 # 0.2 38.2 # 0.2 38.2 # 0.2
PCV (%) 41 # 1 41 # 0.8 40 # 1 43 # 1.5 41 # 0.5 43 # 2
a Significant difference from baseline.
b Significant difference with respect to the LID group (P " 0.05).
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explain the attenuated vasoconstrictor response of the pulmonary 
circulation (41). Despite the observed cardiovascular effects of 
alpha-2 agonists, their use has become more popular in healthy 
patients under going surgery due to their potent analgesic and 
sedative effects. However, the cardiovascular effects of alpha-2 
agonists have not been thoroughly evaluated in dogs undergoing 
surgical stimulation, so it is not known if the changes and their 
magnitude, as determined in this and other studies, are consis-
tent in patients in whom sympathetic activity from nociceptive 
input is more likely to occur. One study demonstrated MAP to 
be stable and within acceptable limits (99 mmHg) with HR of 
49 to 68 beats/min in dogs undergoing soft tissue or orthopedic 
surgery under isoflurane anesthesia, while receiving a CRI of 
1, 2, or 3 !g/kg BW per hour of DEX after IV pre-medication 
with 5 !g/kg BW (5). In another study in dogs undergoing 
ovariohysterectomy, medetomidine (1 !g/kg BW and a CRI of 
1 !g/kg BW per hour) was administered after induction and 
before the start of surgery and decreased HR immediately after, 
but increased steadily to baseline throughout surgery, whereas 
CI did not change from baseline and during surgical stimula-
tion, and SAP remained stable from baseline and only increased 
significantly during removal of the ovaries (9).
A decrease in CO has a direct effect on oxygen delivery 
(DO2), since the latter is the product of the CO and CaO2. 
Consequently, O2ER is also affected since it is the ratio of VO2 
and DO2. Decreases in DO2 and increases in O2ER were shown 
in this and other studies when dexmedetomidine is used (10,17); 
however, if blood lactate concentrations remain unchanged 
despite a decrease in DO2 and an increase in O2ER, it should 
indicate that tissues can maintain aerobic metabolism, reflecting 
that CO is still adequate under these conditions. We did not 
detect changes in lactate concentrations, despite a decrease in 
DO2 and an increase in O2ER. Similarly, lactate levels remained 
unchanged in dogs undergoing surgery while receiving a CRI of 
DEX or medetomidine (5,9). Despite affecting CO, the reduc-
tion in blood flow caused by DEX has been shown in dogs to 
preferentially affect the skin and spleen, whereas blood flow to 
heart, brain, liver, intestine, and kidneys remains well preserved 
and above levels that induce underperfusion, which was also 
supported by unchanged lactate concentrations (14).
In conclusion, the administration of DEX or the combina-
tion of LID-DEX produces significant hemodynamic changes 
resulting in decreased CO, HR, and increased SVR pressure 
and PAOP in dogs anesthetized with sevoflurane; however, such 
changes were not associated with compromised tissue perfusion 
in research healthy dogs.
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